Novo Nordisk’s rebrand to “Novo” and its 2030 strategy at a Capital Markets Day failed to convince some investors, according to analysts cited in coverage. Executives led by CEO Maziar Doustdar outlined plans to launch “more than five multi-blockbusters” annually through 2030 across obesity, diabetes, and additional therapeutic areas. Novo also reiterated targets for risk-adjusted pipeline sales by 2035 and discussed preparing for the loss of U.S. patent exclusivity for semaglutide in 2032. Analysts said the growth expectations appeared in line with peers and may already be priced in, contributing to the lack of investor reassurance. The near-term tone from markets suggests investors want clearer visibility on which clinical or regulatory inflection points will translate into sustained competitive advantage as GLP-1 intensity increases across the sector.